The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival

References

• Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682–91. doi:10.1093/jnci/djh323. PMID:15547181.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502–16. doi:10.1038/nrc1123. PMID:12835670.
   PubMed Web of Science ®Google Scholar
• PDQ Adult Treatment Editorial Board. Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ(R)): health professional version. PDQ cancer information summaries. Natl Cancer Inst (US) Bethesda (MD) 2017;2002. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq. PMID:26389443.
   PubMedGoogle Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–9. doi:10.1038/nature10673. PMID:22193102.
   PubMed Web of Science ®Google Scholar
• Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(5):273–90. doi:10.1038/nrclinonc.2016.25. PMID:26977780.
   PubMed Web of Science ®Google Scholar
• Lavoue V, Thedrez A, Leveque J, Foucher F, Henno S, Jauffret V, Belaud-Rotureau MA, Catros V and Cabillic F. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med. 2013;11:147. doi:10.1186/1479-5876-11-147. PMID:23763830.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. doi:10.1056/NEJMoa020177. PMID:12529460
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43. doi:10.1073/pnas.0509182102. PMID:16344461.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–5. doi:10.1073/pnas.0611533104. PMID:17360651.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203(4):871–81. doi:10.1084/jem.20050930. PMID:16606666.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9. doi:10.1038/nm1093. PMID:15322536.
   PubMed Web of Science ®Google Scholar
• Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39(3):611–21. doi:10.1016/j.immuni.2013.08.025. PMID:24012420.
   PubMed Web of Science ®Google Scholar
• Wouters M, Dijkgraaf EM, Kuijjer ML, Jordanova ES, Hollema H, Welters M, van der Hoeven J, Daemen T, Kroep JR, Nijman HW, et al. Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. Oncoimmunology. 2014;3(12):e962397. doi:10.4161/21624011.2014.962397. PMID:25964862
   PubMed Web of Science ®Google Scholar
• Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S, Wei H. Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(−/low) myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget. 2017;8(44):76843–56. doi:10.18632/oncotarget.20164. PMID:29100353
   PubMedGoogle Scholar
• Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res. 2005;65(15):7000–6. doi:10.1158/0008-5472.can-04-3792. PMID:16061686
   PubMed Web of Science ®Google Scholar
• So KA, Hong JH, Jin HM, Kim JW, Song JY, Lee JK, Lee NW. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study. Gynecol Oncol. 2014;132(3):551–5. doi:10.1016/j.ygyno.2014.01.010. PMID:24440470.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang L, Liu WX, Liu XY. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev. 2015;16(3):933–9. PMID:25735385.
   PubMedGoogle Scholar
• Mabuchi S, Matsumoto Y, Isohashi F, Yoshioka Y, Ohashi H, Morii E, Hamasaki T, Aozasa K, Mutch DG and Kimura T. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol. 2011;122(1):25–32. doi:10.1016/j.ygyno.2011.03.037. PMID:21514632
   PubMed Web of Science ®Google Scholar
• Worley MJ Jr., Nitschmann CC, Shoni M, Vitonis AF, Rauh-Hain JA, Feltmate CM. The significance of preoperative leukocytosis in endometrial carcinoma. Gynecol Oncol. 2012;125(3):561–5. doi:10.1016/j.ygyno.2012.03.043. PMID:22465698
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Welters MJ, van der Burg SH. Monitoring of the immune dysfunction in cancer patients. Vaccines (Basel). 2016;4(3):29. doi:10.3390/vaccines4030029. PMID:27598210.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res. 2016;4(11):895–902. doi:10.1158/2326-6066.cir-16-0197. PMID:27803050
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16(4):219–33. doi:10.1038/nrc.2016.16. PMID:26965076.
   PubMed Web of Science ®Google Scholar
• Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, Griesbeck M, Butler A, Zheng S, Lazo S, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356(6335):eaah4573. doi:10.1126/science.aah4573. PMID:28428369.
   PubMedGoogle Scholar
• Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 2015;26(10):2141–9. doi:10.1093/annonc/mdv309. PMID:26216383
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015;6(31):32228–43. doi:10.18632/oncotarget.4772. PMID:26334096
   PubMed Web of Science ®Google Scholar
• Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334ra52. doi:10.1126/scitranslmed.aad8307. PMID:27075626.
   PubMed Web of Science ®Google Scholar
• Yang JH, Cutler AJ, Ferreira RC, Reading JL, Cooper NJ, Wallace C, Clarke P, Smyth DJ, Boyce CS, Gao GJ, et al. Natural variation in interleukin-2 sensitivity influences regulatory T-Cell frequency and function in individuals with long-standing type 1 diabetes. Diabetes. 2015;64(11):3891–902. doi:10.2337/db15-0516. PMID:26224887.
   PubMed Web of Science ®Google Scholar
• Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604. doi:10.1146/annurev-immunol-020711-074950. PMID:23516985.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, Nortier JW, Welters MJ, Kroep JR, van der Burg SH. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013;73(8):2480–92. doi:10.1158/0008-5472.can-12-3542. PMID:23436796.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–68. doi:10.1038/nri3175. PMID:22437938.
   PubMed Web of Science ®Google Scholar
• Talebian Yazdi M, Loof NM, Franken KL, Taube C, Oostendorp J, Hiemstra PS, Welters MJ and van der Burg SH. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma. Cancer Immunol Immunother. 2015;64(9):1109–21. doi:10.1007/s00262-015-1716-2. PMID:26025564.
   PubMed Web of Science ®Google Scholar
• Wu X, Feng QM, Wang Y, Shi J, Ge HL, Di W. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol Immunother. 2010;59(2):279–91. doi:10.1007/s00262-009-0749-9. PMID:19727719.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–21. doi:10.1158/1078-0432.ccr-05-0883. PMID:16166452.
   PubMed Web of Science ®Google Scholar
• Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16(18):4583–94. doi:10.1158/1078-0432.ccr-10-0733. PMID:20702612.
   PubMed Web of Science ®Google Scholar
• Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met O, Hansen M, Lindberg H, Sengelov L and Svane IM. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study. Cytotherapy. 2017;19(4):500–13. doi:10.1016/j.jcyt.2017.01.007. PMID:28215654.
   PubMed Web of Science ®Google Scholar
• Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011;118(20):5498–505. doi:10.1182/blood-2011-07-365825. PMID:21972293
   PubMed Web of Science ®Google Scholar
• Zhang Z, Huang J, Zhang C, Yang H, Qiu H, Li J, Liu Y, Qin L, Wang L, Hao S, et al. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer Gene Ther. 2015;22(4):198–206. doi:10.1038/cgt.2015.7. PMID:25721210.
   PubMed Web of Science ®Google Scholar
• Martin D, Rodel F, Winkelmann R, Balermpas P, Rodel C, Fokas E. Peripheral leukocytosis is inversely correlated with intratumoral CD8+ T-Cell infiltration and associated with worse outcome after chemoradiotherapy in anal cancer. Front Immunol. 2017;8:1225. doi:10.3389/fimmu.2017.01225. PMID:29085358
   PubMed Web of Science ®Google Scholar
• Weber J, Gibney G, Kudchadkar R, Yu B, Cheng P, Martinez AJ, Kroeger J, Richards A, McCormick L, Moberg V, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4(4):345–53. doi:10.1158/2326-6066.cir-15-0193. PMID:26873574.
   PubMed Web of Science ®Google Scholar
• Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22(12):2908–18. doi:10.1158/1078-0432.ccr-15-2412. PMID:26787752.
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. 2014;2:31. doi:10.1186/s40425-014-0031-3. PMID:26196012.
   PubMedGoogle Scholar
• Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144–53. doi:10.1038/nm.4466. PMID:29309059.
   PubMed Web of Science ®Google Scholar
• Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A. 2010;107(26):11895–9. doi:10.1073/pnas.1006500107. PMID:20547850.
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150. doi:10.1038/ncomms12150. PMID:27381735.
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother. 2015;64(10):1271–86. doi:10.1007/s00262-015-1729-x. PMID:26122357.
   PubMed Web of Science ®Google Scholar